INVA

Innoviva Inc.

Price

$21.15

return (12m)

16.21%

p/e

4.39

p/bv

1.27

DIVIDEND YIELD

0.00%

INVA price

Innoviva

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment INVA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

3.12%

3 months

2.17%

1 year

16.21%

2 years

9.81%

5 years

19.22%

10 years

115.16%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals INVA

Valuation

P/E

4.39

Sector -3.16

Industry -3.16

P/BV

1.27

Sector 1.80

Industry 1.80

P/Revenue (PSR)

3.56

Sector 2.04

Industry 2.04

EV/EBITDA

2.61

Sector -204.34

Industry -204.34

EV/EBIT

2.85

Sector -42.58

Industry -42.58

P/EBITDA

3.28

Sector -19.73

Industry -19.73

P/EBIT

3.58

Sector -67.09

Industry -67.09

P/Total Assets

0.92

Sector 1.06

Industry 1.06

P/Net Current Assets

5.52

Sector -9.56

Industry -9.56

P/Working Capital

2.22

Sector -93.82

Industry -93.82

EPS

4.87

Sector -1.78

Industry -1.78

BVPS

16.80

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

72.19%

Sector 41.28%

Industry 41.28%

EBITDA Margin

-77.26%

Sector -21,198.78%

Industry -21,198.78%

EBIT Margin

36.95%

Sector -35.28%

Industry -35.28%

Net Profit Margins

81.19%

Sector -35.71%

Industry -35.71%

Asset Turnover

0.07

Sector 0.03

Industry 0.03

Profitability

ROE

36.68%

Sector -61.32%

Industry -61.32%

ROA

23.53%

Sector -54.29%

Industry -54.29%

ROIC

13.73%

Sector -1,801.33%

Industry -1,801.33%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

16.01

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-0.67

Sector -20.38

Industry -20.38

Net Debt / EBIT

-0.73

Sector -4.13

Industry -4.13

Net Debt / Equity

-0.26

Sector -33,112.98

Industry -33,112.98

Gross Debt / Equity

0.21

Sector -0.64

Industry -0.64

Equity/Assets

0.72

Sector 0.46

Industry 0.46

Liabilities/Assets

0.28

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

2.34%

Sector -

Industry -

5Y Earnings CAGR

6.09%

Sector -

Industry -

Fundamentals INVA

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Innoviva ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$21.15

Fair Value

$42.91

Upside

102.86%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
INVA Innoviva Inc.	$21.15	16.21%	0.00%	4.39	1.27	36.68%	81.19%
PFE Pfizer Inc.	$30.41	33.97%	5.73%	39.46	2.00	4.97%	6.80%
ABBV AbbVie Inc.	$288.29	36.44%	2.31%	53.66	0.00	-%	14.76%
NVO Novo Nordisk A/S	$40.49	-13.45%	4.66%	9.73	5.17	60.28%	35.32%
MRK Merck & Co. Inc.	$145.20	73.83%	2.27%	116.34	8.79	6.97%	4.77%
AZN AstraZeneca PLC	$185.11	15.21%	1.73%	22.38	5.77	27.27%	16.95%
BMY Bristol-Myers Squibb Company	$62.63	41.99%	5.06%	13.78	5.44	44.06%	18.47%
ZTS Zoetis Inc.	$83.43	-40.99%	2.60%	12.71	10.64	64.91%	27.69%
AMGN Amgen Inc.	$464.48	60.80%	2.13%	28.86	21.58	91.47%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$973.63	52.20%	0.41%	21.68	2.96	14.04%	27.86%
HALO Halozyme Therapeutics Inc.	$130.37	99.98%	0.00%	37.10	106.90	173.67%	24.86%
MCK McKesson Corporation	$1,008.67	24.93%	0.34%	25.96	-30.85	-168.45%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$536.30	26.02%	0.00%	32.22	7.01	23.54%	35.00%
CAH Cardinal Health Inc.	$255.97	35.45%	0.81%	34.74	-21.86	-63.98%	0.67%
ARGX argenx SE	$883.95	8.00%	0.00%	13.26	-	-%	25.42%
HRMY Harmony Biosciences Holdings Inc.	$38.00	33.01%	0.00%	12.39	2.25	20.46%	18.88%
BIIB Biogen Inc.	$251.87	63.27%	0.00%	45.08	2.00	4.58%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

INVA - Historical Dividends

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	09/08/2015	09/30/2015	0.25000000
Dividends	06/10/2015	06/30/2015	0.25000000
Dividends	03/10/2015	03/31/2015	0.25000000
Dividends	11/21/2014	12/23/2014	0.25000000
Dividends	08/26/2014	09/18/2014	0.25000000

ABOUT Innoviva

Innoviva Inc.

Average Investor10 user rating

4.0 (1 people)

United States

30 years

Founded: 1996

2004

Time since IPO - 22 years

5

Employees

Innoviva Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.57 billion, with shareholders equity totaling $1.23 billion.

The company employs approximately 5 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Innoviva Inc. reported $440.00 million in revenue, generating net income of $357.24 million.

Key financial metrics include a P/E ratio of 4.39, a price-to-book (P/B) ratio of 1.27, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INVA.

Market cap

$1.57 billion

Net worth

$1.23 billion

$1,233,262,000.00

Assets

$1.70 billion

$1,702,727,000.00

Total Shares Outstanding

73.42 million

73,421,000

Average Daily Trading Volume

$792.84 Thousand

$792,841.84

Sector

Health Care

Industry

Biotechnology

INVA

INVA revenue and profits

Financial Results INVA

DRAG THE FRAME TO SEE MORE DATA

INVA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$1,008.67 23,56% (12M)

P/E

25.96

0.34%

ROE

-168.45%

P/BV

-30.85

CAH - Cardinal Health

$255.97 35,84% (12M)

P/E

34.74

0.81%

ROE

-63.98%

P/BV

-21.86

ABBV - AbbVie

$288.29 40,35% (12M)

P/E

53.66

2.31%

ROE

P/BV

0.00

MRK - Merck & Co.

$145.20 81,18% (12M)

P/E

116.34

2.27%

ROE

6.97%

P/BV

8.79

AZN - AstraZeneca

$185.11 14,78% (12M)

P/E

22.38

1.73%

ROE

27.27%

P/BV

5.77

PFE - Pfizer

$30.41 33,92% (12M)

P/E

39.46

5.73%

ROE

4.97%

P/BV

2.00

BMY - Bristol-Myers Squibb

$62.63 42,14% (12M)

P/E

13.78

5.06%

ROE

44.06%

P/BV

5.44

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$1,008.67 23,56% (12 M)

P/L

25.96

0.34%

ROE

-168.45%

P/VP

-30.85

CAH - Cardinal Health

$255.97 35,84% (12 M)

P/L

34.74

0.81%

ROE

-63.98%

P/VP

-21.86

ABBV - AbbVie

$288.29 40,35% (12 M)

P/L

53.66

2.31%

ROE

P/VP

0.00

MRK - Merck & Co.

$145.20 81,18% (12 M)

P/L

116.34

2.27%

ROE

6.97%

P/VP

8.79

AZN - AstraZeneca

$185.11 14,78% (12 M)

P/L

22.38

1.73%

ROE

27.27%

P/VP

5.77

PFE - Pfizer

$30.41 33,92% (12 M)

P/L

39.46

5.73%

ROE

4.97%

P/VP

2.00

BMY - Bristol-Myers Squibb

$62.63 42,14% (12 M)

P/L

13.78

5.06%

ROE

44.06%

P/VP

5.44

Frequently Asked Questions

What is the price of Innoviva (INVA) today?

The current price of Innoviva (INVA) is $21.15. The stock began the year trading around $19.99 and is currently priced at $21.15. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Innoviva (INVA) pay dividends?

Innoviva (INVA) did not pay dividends over the past year.

Is Innoviva (INVA) a good investment?

Innoviva (INVA) is currently trading at $21.15 with a P/E ratio of 4.39. This represents a 1,328% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 16.21%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Innoviva (INVA) stock?

You can buy Innoviva (INVA) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol INVA and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Innoviva (INVA) yield today?

Over the past month, Innoviva (INVA) has returned 3.12% — 16.21% over the past year, and 19.22% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Innoviva (INVA) today at the current price of $21.15 your total investment would be $2,115.00.

Based on historical performance, the investment would have grown to approximately:

$2,457.84 after 1 year
$2,521.50 after 5 years
$4,550.63 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

INVA

Innoviva Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment INVA

Target price created!

Delete target price?

Your Target Price strategy deserves unlimited alerts

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING INVA WITH OTHER STOCKS

type

Ex - Dividend Date

payment date

value

ABOUT Innoviva

Innoviva Inc.

United States

30 years

2004

5

PROFIT X PRICE INVA

Financial Results INVA

INVA cash flow

Asset, Revenue and Profit Growth - INVA

INVA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions